scout
|Articles|November 1, 2007

Oncology NEWS International

  • Oncology NEWS International Vol 16 No 11
  • Volume 16
  • Issue 11

MB07133 gets orphan drug status

MB07133 gets orphan drug status

SAN DIEGO—Metabasis Therapeutics' MB07133 has received orphan drug status from FDA for the treatment of hepatocellular carcinoma. MB07133 is a novel HepDirect prodrug of cytarabine monophosphate designed to produce the oncolytically active form, cytarabine triphosphate, in the liver tumor where it acts to inhibit cell proliferation and induce apoptosis.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.


Latest CME